Selskabets formål er at drive handelsvirksomhed med farmaceutiske produkter, herunder udvikling, salg, distribution og markedsføring af farmaceutiske produkter og dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 71.4 mio. | 48 t. | 51.2 mio. | 2.1 mio. | 0 | |
CVR: 36699051
Secondary names: Pharmamentum ApS, Pharmanovia Denmark ApS
Previous names: Pharmamentum ApS
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Mohammad Muqtadir Samy joined the board
Amit Vijaykumar Patel left the board
Mohammad Muqtadir Samy left the board
Twan Johannes Anna Nouwen joined the board
Mohammad Muqtadir Samy joined the board
Christoph Michael Habereder joined the board
Santsagar Patel left the board
CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB appointed as auditor
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB resigned as auditor
James Sang Bum Lee left the board
Atnahs Pharma Denmark ApS has demonstrated a fluctuating financial trajectory, with significant revenue growth peaking at 517.2 million DKK in 2023, followed by a sharp decline to 71.4 million DKK in 2025. Despite this revenue volatility, the company has maintained profitability, albeit at low levels, with profits of 14.7 million DKK in 2023 and only 47,843 DKK in 2025. The equity position has improved from negative 3.5 million DKK in 2021 to over 2 million DKK in 2025, indicating a recovery, though concerns remain regarding low profit margins and the sustainability of revenue. Positioned within the pharmaceutical wholesale industry, Atnahs Pharma's size and fluctuating performance suggest a need for strategic adjustments to stabilize growth and enhance profitability.
AI-generated summary
Companies in the same industry and area
CVR 39371049
CVR 46267788
CVR 40299939
CVR 32173276
CVR 25004035
companydata.dk